Artizan, a Yale University spinout focused on intestinal microbiota targets potentially responsible for inflammatory bowel disease, has been backed by investors including Brii Biosciences, bringing its total funding to $12m.
Artizan, a US-based inflammatory disease therapy spinout of Yale University targeting the intestinal microbiota, yesterday closed a series A round of undisclosed size that included medicines supplier Brii Biosciences.
While Artizan did not confirm the size of the investment, it noted it had now obtained a total of $12m in funding. The spinout secured $5m in funding in March 2019, according to a securities document.
Brii Biosciences invested as part of a collaboration deal with Artizan. The round’s…
